Premium
Pseudoporphyria and Nonsteroidal Antiinflammatory Agents in Children with Juvenile Idiopathic Arthritis
Author(s) -
De Silva Bernadette,
Banney Leith,
Uttley William,
Luqmani Raashid,
Schofield Olivia
Publication year - 2000
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1046/j.1525-1470.2000.01827.x
Subject(s) - medicine , naproxen , nonsteroidal , dermatology , etiology , arthritis , erythema , juvenile , prospective cohort study , juvenile rheumatoid arthritis , rheumatology , alternative medicine , pathology , biology , genetics
Pseudoporphyria is characterized by erythema, blistering, and scarring on sun‐exposed skin. Nonsteroidal antiinflammatory drugs (NSAIDs) are implicated in the etiology of this condition. In a 1‐year prospective study of children attending the pediatric rheumatology clinic in Edinburgh we found a prevalence of pseudoporphyria of 10.9% in children taking NSAIDs for juvenile idiopathic arthritis. Naproxen was the most commonly implicated NSAID, independent of dosage. Blue/gray eye color was an independent risk factor for the development of pseudoporphyria. We would advise caution in prescribing naproxen in these children to prevent disfiguring facial scarring.